Abstract
This report is based on a session held during the 13th Annual Meeting of the British Uro-oncology Group (BUG) in London in September 2016. The session discussed the clinical implications of genomics in the management of advanced prostate cancer, in the context of the potential use of biomarkers to predict outcomes to treatment and the future of biomarker-driven trials.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
